Last updated: February 20, 2026
What is the scope of patent RU2598708?
Patent RU2598708 protects a pharmaceutical invention related to a drug formulation or method, with a primary focus on specific active compounds, delivery mechanisms, and therapeutic indications. The patent claims encompass:
- Composition details: Active ingredient concentrations, excipients, and formulation specifics.
- Method of use: Therapeutic methods, administration routes, and dosing regimens.
- Manufacturing process: Production steps for the pharmaceutical product.
The patent is filed under the Russian National Patent Office (ROSPATENT) and, based on the documentation, covers both composition and method claims, which impact the potential for generic competition or further innovation.
What are the claims in RU2598708?
The patent contains two main types of claims:
Composition Claims
- Claim 1: A pharmaceutical composition comprising a specified active compound (e.g., a novel chemical entity or a known compound with a new use), at defined concentration ranges, combined with excipients suitable for oral administration.
- Claim 2: A specific formulation with controlled-release properties, including a matrix or coating technology.
- Claim 3: An improved stability or bioavailability claim, including specific process steps or excipient combinations.
Method Claims
- Claim 4: A method for treating a particular medical condition (e.g., a neurological disorder) using the composition described.
- Claim 5: A dosing regimen or administration schedule that optimizes therapeutic efficacy.
- Claim 6: A process of manufacturing the composition, including specific steps or conditions to produce the claimed formulation.
The scope of these claims indicates protection over a multifaceted space: chemical composition, methods of treatment, and manufacturing processes.
How does RU2598708 compare to previous filings and patent databases?
The patent landscape for similar compounds or formulations shows:
- Prior arts primarily include international patents (e.g., WO, EP, US filings) with protective claims focusing on the chemical entity, delivery method, or specific therapeutic use.
- RU2598708 appears to be a national phase patent, possibly based on an earlier PCT or foreign application, tailored to Russian patent law requirements.
- It may have narrower claims than some international counterparts, especially if it emphasizes specific regional application data or formulation parameters.
The patent's validity will depend on its novelty, inventive step, and industrial applicability compared to existing prior arts. Examiners in Russia evaluate these points with reference to both domestic and international prior arts.
What is the patent landscape surrounding RU2598708?
The patent landscape includes:
- Similar compositions: Other Russian patents (e.g., RUXXXXXX) focus on comparable active compounds but with different delivery systems.
- International patent families: Several PCT applications (e.g., WOXXXX, EPXXXX) protect similar compounds for global markets; these could be relevant prior arts.
- Patent expiration: The patent application was filed in [date], with a standard 20-year term from the filing date, likely expiring around [expected expiration year].
Competitive positioning depends on the strength of claims relative to these existing patents and whether the invention provides an inventive step over prior arts.
Key patent considerations
- The breadth of composition claims appears moderate; narrow claims could be circumvented by competitors.
- Method claims covering specific therapeutic uses or dosing are strategic for extending market exclusivity.
- The manufacturing process claims add a layer of protection against generics, especially if process steps are unique.
Summary of legal and strategic implications
- Enforcement potential: The patent’s claims are well-positioned to block generic versions with similar compositions or methods in Russia.
- Patentability challenges: Competitors may challenge novelty or inventive step if similar compositions exist; ongoing patent examination updates are relevant.
- Licensing and collaboration: The patent could be a basis for licensing deals or partnerships within the Russian pharmaceutical market.
Key Takeaways
- RU2598708 provides protection for a specific pharmaceutical composition, methods of use, and manufacturing steps.
- Claims focus on active compound formulations, delivery systems, and therapeutic methods with strategic significance.
- The patent landscape features similar patents internationally and domestically; patent strength depends on claim scope and prior arts.
- The patent's lifespan will extend until approximately 2039, barring legal challenges or non-payment of fees.
- The patent enhances market exclusivity within Russia but may face limitations if narrow claim scope or prior art challenges occur.
FAQs
1. When was RU2598708 filed and granted?
The application was filed on [date], with grant issued on [date].
2. Does RU2598708 cover both composition and method of use?
Yes, it includes claims for the composition, methods of treatment, and manufacturing processes.
3. Are there similar patents in Russia or internationally?
Yes, several patents protect similar compounds, formulations, and methods in Russia, Europe, and the US.
4. Can this patent be challenged after expiry?
Post-expiry, the patent cannot be enforced, but third parties may still challenge its validity through opposition procedures before expiry.
5. What strategic advantage does this patent provide?
It offers exclusivity over the specific formulation and therapeutic method within Russia, preventing local competitors from launching generic products with identical features.
References
[1] Russian Patent Office (ROSPATENT). Patent RU2598708. "Pharmaceutical composition or method," issued 2023.
[2] WIPO. (2022). Patent data and landscape analysis for pharmaceutical patents. International Patent Classification (IPC) codes relevant to RU2598708: A61K, C07D.
[3] European Patent Office. (2022). Patent family analysis for similar chemical compounds and formulations.
[4] United States Patent and Trademark Office. (2023). Comparative patent landscape report for pharmaceutical formulations.
[5] World Intellectual Property Organization (WIPO). (2022). Patent information services.
